Abstract. Eleven newly diagnosed insulin dependent patients were studied before and during the first 16 h after start of insulin treatment. All the patients were found to have significant amounts of C-peptide in plasma indicating residual insulin secretion. The fall in blood glucose after start of insulin therapy was followed by a parallel decrease in C-peptide (R = 0.99, P < 0.01) suggesting that the beta-cells may respond to variation in blood glucose. Eight of the patients were studied 1, 4, 7, 14, 90 and 180 days after start of insulin therapy. During the first 90 days of treatment an increasing maximal C-peptide concentration was found after a standard breakfast test meal.
Abstract. Eleven newly diagnosed insulin dependent patients were studied before and during the first 16 h after start of insulin treatment. All the patients were found to have significant amounts of C-peptide in plasma indicating residual insulin secretion. The fall in blood glucose after start of insulin therapy was followed by a parallel decrease in C-peptide (R = 0.99, P < 0. 01) suggesting that the beta-cells may respond to variation in blood glucose. Eight of the patients were studied 1, 4, 7, 14, 90 and 180 days after start of insulin therapy. During the first 90 days of treatment an increasing maximal C-peptide concentration was found after a standard breakfast test meal. Two thirds of this improvement i beta-cell function was found after the initial 14 days with an average increase in maximal C-peptide of 260 per cent. The sensitivity to glucose improved.
The onset of ketosis prone diabetes mellitus is associated with severe beta-cell failure (Enk 1977;  Ludvigsson Block et al. 1972; Heinze et al. 1979) . In 12 children with IDDM Ludvigsson & Heding (1978) found C-peptide immunoreactivity in all on admission to hospital. Block et al. (1972) found no C-peptide immunoreactivity in 3 of 4 patients during initial ketoacidosis, but 2-20 weeks later beta-cell function was found in all. This is in accordance with the findings of Faber & Binder (1977a) , who found residual betacell function in all of 17 patients one month after start of insulin treatment.
The purpose of the present study was to follow the beta-cell function from the time of diagnosis and during the first weeks of treatment as well as to study the interrelationship between blood glucose variations and insulin secretion.
Material and Methods
Eleven insulin dependent patients were studied before (0-day) and 1, 4, 7, 14, 90 and 180 days after diagnosis and start of insulin treatment. The patients were con¬ sidered insulin dependent according to the following criteria at admission to hospital: glucosuria > 57c, signi¬ ficant ketonuria (more than or equal to ++ with Ketostix), body weight below 110% of the ideal for sex and height (Natvig 1956) Heding (1975) employing the antiserum M1230 ). The within and between assay coefficients of variation to C-peptide were 3.2% and 9.6% respectively . The cross-reactivity with human proinsulin is very low with antiserum M1230. Thus the proinsulin has to exceed normal fasting level with a factor of more than 200 before any proinsulin is measured as CPR (Faber et al. 1978) . With this antiserum a C-peptide concentration of 0.06 pmol/ml or more implies residual insulin secretion ). Plasma insulin concentration (IRI) was measured radioimmunologically using ethanol for the precipitation of the antigen-antibody complex (Heding 1972 
Results
On admission to hospital all 11 patients had signi¬ ficant amounts of C-peptide in plasma, 0.21 pmol/ ml, range: 0.06-0.34. Neither blood glucose nor total carbon dioxide was correlated to C-peptide at admission. The fall in blood glucose after start of insulin therapy (Fig. 1 ) was followed by a parallel decrease in C-peptide (R = 0.99, P < 0.01), when calculated from the average values. No correlation was found between C-peptide and IRI.
In the 8 patients, who were followed prospectively (Fig. 2) As a group a significant gradual decrease in glucosuria/24 h and mean blood glucose was found during the first 14 days, in spite of no day-to-day variation in average insulin dose after the third day (Fig. 2) . The glucosuria/24 h after 90 and 180 days was 6 ± 4 g/24 h and 14 ± 7 g/24 h, respectively. This was found in spite of and average reduction in insulin dose, of (0.27 ± 0.04 IU/24 h) and (0.28 ± 0.04 IU/24 h) (P < 0.05), respectively, when compared to the dose at discharge from the hospital.
Discussion
In this study we found measurable C-peptide in all of 11 patients before start of insulin therapy. None of the patients had severe ketoacidosis at onset, and on an average C-peptide values were about 20 per cent of the maximal levels found in normals during every day life (Faber & Binder 1977b) . Presumably this represents the maximal secretory capacity at time of onset because of the high stimulating glucose level. We do, however, not know whether the C-peptide level would increase further after additional stimuli, ex. glucagon. The 
